Use of acetylsalicylic acid in primary prevention: new evidence

Authors

DOI:

https://doi.org/10.23925/1984-4840.2019v21i4a10

Keywords:

aspirina, prevenção primária, acidente vascular cerebral, fatores de risco

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biography

André Leonardo Fidelis de Moura, Centro Universitário Barão de Mauá, Medicina – Ribeirão Preto (SP), Brasil.

Cardiologia, Subespecialista em Estimulação Cardíaca Artificial pela Sociedade Beneficente e Hospitalar Santa Casa de Misericórdia de Ribeirão Preto - São Paulo, Médico Assistente da Disciplina de Clínica Médica do Centro Universitário Barão de Mauá - Ribeirão Preto, SP – Brasil.

References

Gaziano JM, Brotons C, Cappolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46. DOI: http://doi.org/10.1016/S0140-6736(18)31924-X

ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39. DOI: http://doi.org/10.1056/NEJMoa1804988

McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509-18. DOI: http://doi.org/10.1056/NEJMoa1805819

Published

2020-05-29

How to Cite

1.
Mantovani CML, Pinato GR, Moura ALF de. Use of acetylsalicylic acid in primary prevention: new evidence. Rev. Fac. Ciênc. Méd. Sorocaba [Internet]. 2020May29 [cited 2024Jul.3];21(4):191-2. Available from: https://revistas.pucsp.br/index.php/RFCMS/article/view/41443

Issue

Section

Literature Notes